We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Terumo Blood and Cell Technologies’ Platelet Pooling Set Cleared by FDA

The Terumo Blood and Cell Technologies logo
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Terumo Blood and Cell Technologies has announced US Food and Drug Administration (FDA) clearance and official launch of its IMUGARD(R)WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days.1 IMUGARD is the first platelet pooling set approved for seven-day storage in the US and provides an alternate source of platelet supply at a time when demand continues to increase while the supply remains challenged by the lack of blood donors.


Terumo Blood and Cell Technologies is a medical technology company that makes products that collect, process and separate blood and cells. Platelets are a component of human blood that form clots and stop bleeding. They are used to treat many different patients, such as those undergoing chemotherapy, organ transplants and bone marrow transplants. In 2021, more than 2.5 million units of platelets were transfused in the US, up from 2.3 million in 2019, according to the National Blood Collection and Utilization Survey (NBCUS).


Terumo Blood and Cell Technologies’ latest innovation aims to increase the availability of platelets for transfusion. IMUGARD enables extended shelf life of platelets from the standard five days to seven days.1 This can help blood centers better manage supply to meet patient needs and reduce waste.2,3


Most of the platelets in the United States are currently collected by apheresis. IMUGARD now gives blood centers another product choice to help them recoup platelets from whole blood donations.


“We continue to invest in innovations that help blood centers to positively impact patients,” says Chetan Makam, General Manager, Global Blood Solutions, Terumo Blood and Cell Technologies. “IMUGARD opens the possibility for US blood centers to use the platelets from their whole blood donations to increase the number of platelets available for transfusion. We are the first company to provide seven-day shelf life of both apheresis and whole blood-derived platelets in the US, adding flexibility to the platelet supply. This is especially important now with the increased demand for platelets and the challenges blood centers face with recruiting new apheresis platelet donors.”


1 U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion. December 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacterial-risk-control-strategies-blood-collection-establishments-and-transfusion-services-enhance.

2 Delage G, Bernier F, Beaudoin J, Thibault S, Dion J, Gagné L. Improved bacterial culture of platelet product: preliminary results after implementation of a two-bottle system with 48-hour sampling. Transfusion. 2016:56(S4);28A. 

3 Harm SK, Szczepiorkowski ZM, Dunbar NM. Routine use of Day 6 and Day 7 platelets with rapid testing: two hospitals assess impact 1 year after implementation. Transfusion. 2018;58(4):938-942.